Key result
Transvenous ICD provides secondary prevention for atypical ventricular fibrillation in PRKAG2 syndrome.
Why the study?
PRKAG2 syndrome is a rare glycogen storage cardiomyopathy with atypical arrhythmias and unclear risk stratification for ventricular fibrillation and sudden cardiac arrest.
Case Report (n=1)
This case highlights atypical arrhythmic presentations in PRKAG2 cardiomyopathy, underscoring the importance of individualized risk assessment and early ICD consideration.
Alerts clinicians to arrest risk in young PRKAG2 patients despite preserved function; leaves open risk-stratification and prevention strategies.
BACKGROUND: PRKAG2 syndrome is a rare autosomal dominant glycogen storage cardiomyopathy characterized by left ventricular hypertrophy, ventricular pre-excitation, and progressive conduction system disease. CASE SUMMARY: We report the case of a 25-year-old woman with genetically confirmed PRKAG2 syndrome who presented with an out-of-hospital cardiac arrest. Echocardiography revealed preserved left ventricular systolic function with mild concentric hypertrophy and marked apical thickening. Cardiac magnetic resonance imaging showed anterolateral trabecular hypertrophy without evidence of myocardial fibrosis. Electrophysiological study excluded Wolff-Parkinson-White syndrome and instead identified a fasciculoventricular accessory pathway. Given the occurrence of ventricular fibrillation and the associated arrhythmic risk, a transvenous implantable cardioverter-defibrillator was implanted for secondary prevention. DISCUSSION: This case illustrates the atypical presentation of arrhythmias that deviate from classical patterns, such as those seen in Wolff-Parkinson-White syndrome. TAKE-HOME MESSAGE: Individualized risk assessment, close electrophysiological monitoring, and consideration of early implantable cardioverter-defibrillator implantation are important in PRKAG2-related cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Visch et al. (2026) conducted a case report in PRKAG2 syndrome (n=1). Transvenous implantable cardioverter-defibrillator was evaluated. A 25-year-old woman with genetically confirmed PRKAG2 syndrome and ventricular fibrillation deviating from classical patterns received a transvenous ICD for secondary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: